IP Library › Granted Patent US 9,527,888
Granted Patent B2
US 9,527,888 · App. 14/400,321 · Granted Dec 27, 2016

Anti-inflammatory peptides and composition comprising the same

Inventors: Sang Jae Kim (Seoul, KR); Kyung Hee Kim (Seongnam-si, KR); Kyu-Yong Lee (Seongnam-si, KR); Seong-Ho Koh (Seongnam-si, KR); Hyun-Hee Park (Seongnam-si, KR); Sung Jin Huh (Seongnam-si, KR); Woo Jin Lee (Seongnam-si, KR); Bum Joon Kim (Seongnam-si, KR)
Assignee: GemVax & KAEL Co., Ltd.
C07K7/08A23L33/18A61K8/64C07K14/4703C12N9/0069C12N9/0083C12Y113/11C12Y114/99001A23V2002/00A61Q19/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,527,888
App. No.
14/400,321
Granted
Dec 27, 2016
Kind
B2
Abstract

A peptide with anti-inflammatory activity is described, wherein the peptide comprises at least one amino acid sequence among SEQ ID NO: 2 to SEQ ID NO: 179, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The peptides that have at least one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 179 shows outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising those peptides can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases.

Claims (3)

1. A composition comprising an isolated peptide 6 amino acids in length having the amino acid sequence of SEQ ID NO: 117.

2. The composition of claim 1 , comprising 0.1 μg/mg to 1 mg/mg of the isolated peptide.

3. The composition of claim 1 , wherein the composition is a pharmaceutical composition formulated for oral, rectal, transdermal, intravenous, intramuscular, intraperitoneal, intramedullary, epidural, or subcutaneous administration.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2023
From: GEMVAX & KAEL CO. LTD.
To: GEMVAX & KAEL CO. LTD.; KIM, SANG JAE
Reel/Frame 065471/0754 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 24, 2015
From: KIM, KYUNG HEE; LEE, KYU-YONG; KOH, SEONG-HO; PARK, HYUN-HEE; HUH, SUNG JIN; LEE, WOO JIN; KIM, BUM JOON
To: GEMVAX & KAEL CO., LTD.
Reel/Frame 036169/0738 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 24, 2015
From: KIM, SANG JAE
To: GEMVAX & KAEL CO., LTD.
Reel/Frame 036177/0700 →
Priority Claims (5)
KR 10-2012-0050529 · May 11, 2012 · national
KR 10-2012-0050533 · May 11, 2012 · national
KR 10-2012-0071989 · Jul 2, 2012 · national
KR 10-2012-0104144 · Sep 19, 2012 · national
KR 10-2012-0104207 · Sep 19, 2012 · national
Continuity (1)
Related Publication 20150099693A1 · Apr 9, 2015